NGLY1 and melanoma: Similar alteration patterns associated with the differentially abundant proteins identified in the NGLY1-knockdown cells were observed in melanoma cells treated with NM-350 (Supplementary Table S4), further supporting the NGLY1-inhibitory and anticancer activity of our novel compounds.